Ascletis Pharma Inc. (HKEX code: 1672) announces today that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis (NASH) drug candidate ASC40 (TVB-2640) in 34 Chinese subjects has been completed and data indicates that key pharma